1/9

SITSTGGGTYHAE SITSTGGGTYHAE SITSTGGGTYHAE XXXXXXXXXXXX **MGQGSSVTVSS** ---TP---I ROAPGEGLEWVA DDYGGQSTYVMDA XXXXXXXXXXXXXXXXX DDYGGQSTYVMDA DDYGGQSTYVMDA 3 8 NYWMT NYWMT XXXXX S ပ FS RFTISRDNSKSTLYLQMNSLRPEDTATY | ------GV--F---GV---GN--Ē ESGGDLVQPGRSLKLSCVASGF | ----GV------SS----R---SS---Ø QVQL SVKG XXX SVKG SVKG

EG.

KOL:

KOLWIZVH-1

KOLWIZVH-2

H KOL:

KOL:

KOL:

KOL:

KOLWIZVH-1

KOLWIZVH-1

KOLWIZVH-1

Attorney Docket No. 40923-0060-US2

2/9

L' XXXXXX GATWLAA GATTNLAA GATTNLAA IO----GTKLER QOKPGKSPRLLIY --T---A-K------T---A-K---FG --A-K XXXXXXXXXX LHHSEYPYT LHHSEYPYT LHHSEYPYT (L, × SLTINSLESEDMAIYYC Y TF--SS-QP--I-T---3 TF--SS-QP--I-T--١ TF--SS-QP--I-T--RASQDIGNYLR XXXXXXXXXX RASQDIGNYLR RASQDIGNYLR DIQLTQSPASLPASLGDRVTITC ----W----Ŀ 1 ā S -S--S-SG R G GVPSRFSGS

HG.2

SUBSTITUTE SHEET (RULE 26)

REIWIZVKRS:

REIWI2VK:

RATWIZVK:

REI:

REIWIZVKRS:

REIWI2VK

RATWIZVK:

REI:

3/9

FIG.3A

oligo 21 caggtccaactgcaggagtcagggggaggtgtagtgcagcctggaa


PBtI

GTCCAGGTTGACGTCCTCCACTCCACATCACGTCGGACCTTCCAGAGACTCTGAA [01igo 180 **caggtccaa**ctgcaggagtcagggggggggtgtagtgcagcctggaaggtctgtgagactt TCCIGIAGCICAICIGGAIICACAIICAGIAAIIACIGGAIGACIIGGAIACGCCAGGCI [oligo K]<u>Aggacatcgagtagacctaagtgtaagtcattaatgacctactgaacctatgcgg</u>tccga ccaacgcaggtaatgatcatgaccaccaccatggatggta [oligo K]<u>ggrccctrcccagaacttacccaacgtaatga</u>rcatgaccaccaccatggargta u æ K Q H S t K 3 U O Ø S (Q to V mutation needed) O S U Ē U > Ŋ 3 ы U Ш O S S U S K U U O ທ D, 61 K)

Shui-on LEUNG et al.
"Humanization of an Anti-Carcinoembryonic Antigen Anti-Idiotype
Antibody as a Tumor..."
Attorney Docket No. 40923-0060-US2

-	. <del>-</del>	240 [oligo	1	(	300	1		360 1	
oligo FIG.3B	23 atgcagagtctgtgaagggccgattcactatctccagagataattcaa [AlwNI] GCAGAGTCTGTGAAGGGCCGATTCACTATCTCCAGAGATAATTCAAAAAAACCCCTGTTC	181+++++++	cgtctcagacactt (oligo 22) A E S V K G R F T I S R D N S K N T L F	CTGCAAATGGACAGTCTGAGGCCTGAGGACACGGGCGTTTATTACTGTTCAAGAGATGAC	(oligo L) GACGITIACCIGICAGACICCGGACICCIGIGCCCGCAAATAAIGACAAGIICITATIG	LQMDSLRPEDTGVYYCSR <u>DD</u>	[Beteii] 301	ATGCCTCCTGTCGATACATACCTACGGACCCCAGTCCCTTGAGGCCAGTGGCAG CAAtacctacggaccccagtcccttgaggccagtggcag	aggagg (ottgo 24) S S -

## FIG.4A



Attorney Docket No. 40923-0060-US2

K

×

Ø

K


H

C

## FIG.4B

[oligo N] CTTCTATAACGATGAATAATGACAGACGTGGTAAGACTCATAGGTATGTGCAAACCTTAA [oligo N] GCCAAGTCACCGTCACCCAGACCCTGTCTAAAATGAAAATGGTAGAGTTCGGAAGTCGG tgtgcaaaccttaa **CGGTTCAGTGGCAGTCTGGGACAGATTTTACTTTTACCATCTCAAGCCTTCAGCCT** gaagatattgctacttattactgtgtgcaccattctgagtatccatacacgtttggaatt S S H coctggttcaacg<u>tctaga</u>ttgcac (oligo 28) (oligo N) <u>cccrccrr</u>caaccrcracrrccac H GGCACCAAGTIGCAGATCAAACGTG cggttcagtggcagtgggtctggg U U S C S C æ S 回 181 241 301

<del>-</del> / 0



% Binding of Peroxidase conjugated MN-14

Shui-on LEUNG et al.
"Humanization of an Anti-Carcinoembryonic Antigen Anti-Idiotype
Antibody as a Tumor..." Attorney Docket No. 40923-0060-US2

-			
GACATTCAGC CTGTAAGTCG D I Q L	ACIGGICAG AGGICGAAGG	CTGCCTGCGT CTCTGGGAGA GACGGACGCA GAGACCCTCT L P A S L G D	50
CAGAGTCACT GTCTCAGTGA R V T	ATTACTTGCC GGGCAAGTCA TAATGAACGG CCCGTTCAGT I T C R A S O	AGACATTGGA AATTATTTAA TCTGTAACCT TTAATAAATT D I G N Y L R CDR1	100
GATGGTTCCA CTACCAAGGT W F Q	GCAGAAACCG GGGAAATCTC CGTCTTTGGC CCCTTTAGAG Q K P G K S P	CGAGGCTTTT GATTTATGGT GCTCCGAAAA CTAAATACCA R L L I Y <u>G</u>	150
CGIIGGIIGN	TGGCAGCTGG GGTCCCATCA ACCGTCGACC CCAGGGTAGT A A G V P S	CGGTTCAGTC GCAGTAGGTC GCCAAGTCAC CGTCATCCAG R F S G S R S	200
TGGGTCAGAT ACCCAGTCTA G S D	AAAAGAGACT GGTAGTTGTC	CCTGGAGTCT GAAGATATGG GGACCTCAGA CTTCTATACC L E S E D M A	250
CTATTTATTA GATAAATAAT I Y Y	GACAGACGTG GTAAGACTCA	ATCCATACAC GTTTGGAATT TAGGTATGTC CAAACCTTAA PYT FGI	300
GGGACCAAGC CCCTGGTTCG G T K L	TGGAACGGAA ACGG ACCTTGCCTT TGCC E R K R		324

FIG.6

GTCCAGGTTG ACGTCCTCA	C AGGGGGAGAT CTAGTGCAGC G TCCCCCTCTA GATCACGTCG G G D L V Q P	CTGGAAGGTC 50 GACCTTCCAG G R S
TCTGAAACTT TCCTGTGTAAAGACTTTGAA AGGACACATAAL	CCTCTGGATT CACATTCAGT CGGAGACCTAA GTGTAAGTCA SGFTFS	AATTACTGGA 100 TTAATGACCT N Y W M CDR1
TGACTTGGAT CCGCCAGGC ACTGAACCTA GGCGGTCCG TWIRQA	CCAGGGGAGG GTCTTGAATG GGTCCCCTCC CAGAACTTAC P G E G L E W	GGTTGCGTCC 150 CCAACGCAGG V A S
ATTACTAGTA CTGGTGGTG TAATGATCAT GACCACCAC I T S T G G G	G GACTTACCAT GCAGAGTCTG CTGAATGGTA CGTCTCAGAC T Y H A E S V CDR2	ACTTCCCGGC
TAAGTGATAG AGGTCTCTA	ATTCAAAAAG CACCCTGTAC TAAGTTTTTC GTGGGACATG S K S T L Y	CTGCAAATGA 250 GACGTTTACT L Q M N
ACAGTCTGAG GCCTGAGGA TGTCAGACTC CGGACTCCTC S L R P E D	C ACGGCCACTT ATTACTGTTC G TGCCGGTGAA TAATGACAAG T A T Y Y C S	AAGAGATAGAC 300 TTCTCTATCTG R D D
TACGGAGGAC AGAGCACCT. ATGCCTCCTG TCTCGTGGA: Y G G O S T Y CDR3	A TGTTATGGAT GCCTGGGGTC T ACAATACCTA CGGACCCCAG V M D A W G Q	TCCCTAGAAG
GGTCACCGTC TCCTCA CCAGTGGCAG AGGAGT V T V S S		376

FIG.7